Tsimberidou AM, et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021;14(1):102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.

Article  CAS  PubMed  Google Scholar 

Gattinoni L, et al. T memory stem cells in health and disease. Nat Med. 2017;23(1):18–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude SL, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.

Article  PubMed  PubMed Central  Google Scholar 

Guzman G, et al. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479–89.

Article  PubMed  PubMed Central  Google Scholar 

Norelli M, et al. Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta. 2016;1865(1):90–100.

CAS  PubMed  Google Scholar 

Stadtmauer EA, et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Adv. 2019;3(13):2022–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sommer C, et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol Ther. 2019;27(6):1126–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng Q, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen GM, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11(9):2186–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bai Z, et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. J Immunother Cancer. 2021;9:5.

Article  Google Scholar 

Bai Z, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8(23):eabj2820.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haradhvala NJ, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28(9):1848–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science. 2020;370(6522):1328–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossi J, et al. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. Blood. 2018;132(8):804–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Angelo SP, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sekine T, et al. TOX is expressed by exhausted and polyfunctional human effector memory CD8(+) T cells. Sci Immunol. 2020;5(49):eaba7918.

Article  CAS  PubMed  Google Scholar 

Guo Y, et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res. 2018;24(6):1277–86.

Article  CAS  PubMed  Google Scholar 

Locke FL, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898–911.

Article  PubMed  PubMed Central  Google Scholar 

Sheih A, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11(1):219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dickinson MJ, et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 2023;13(9):1982–97.

Article  PubMed  PubMed Central  Google Scholar 

Lisiero DN, et al. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model. J Immunol. 2011;186(9):5068–77.

Article  CAS  PubMed  Google Scholar 

van Leeuwen EM, et al. Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol. 2005;17(6):713–9.

Article  PubMed  Google Scholar 

Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med. 2003;198(9):1369–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carr JM, et al. CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proc Natl Acad Sci U S A. 2006;103(51):19454–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raje N, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kirouac DC, et al. Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat Biotechnol. 2023. https://doi.org/10.1038/s41587-023-01687-x.

Article  PubMed  Google Scholar 

Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007;25:171–92.

Article  CAS  PubMed  Google Scholar 

Behr FM, et al. Armed and ready: transcriptional regulation of tissue-resident memory CD8 T cells. Front Immunol. 2018;9:1770.

Article  PubMed  PubMed Central  Google Scholar 

Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35(2):51–60.

Article  CAS  PubMed  Google Scholar 

Chen Y, et al. BATF regulates progenitor to cytolytic effector CD8(+) T cell transition during chronic viral infection. Nat Immunol. 2021;22(8):996–1007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kallies A, Zehn D, Utzschneider DT. Precursor exhausted T cells: key to successful immunotherapy? Nat Rev Immunol. 2020;20(2):128–36.

Article  CAS